Han Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Han Cai has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Alexander J. Clarke
Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
1 shared publication - Audrey Gérard
The Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
1 shared publication - Benjamin Alexis Fisher
University of Birmingham School of Infection, Inflammation and Immunology Birmingham
1 shared publication - Benjamin Demarco
Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
1 shared publication - Esther L. Jones
Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
1 shared publication - Gemma Harris
Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot, UK
1 shared publication
Latest Publications
- 17 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (118) , eads9680
The autoantigen TRIM21 assembles proinflammatory immune complexes after lytic cell death
Sjögren’s disease (SjD) causes localized and systemic inflammation and autoantibody production against intracellular proteins such as TRIM21/Ro52 (tripartite motif-containing protein 21). TRIM21, an E3 ubiquitin ligase, binds antibody Fc domains on opsonized pathogens that have escaped extracellular immunity and entered the cytosol. TRIM21 then ubiquitinates these pathogens, driving their proteasomal degradation. How TRIM21 becomes an autoantigen remains unclear. We show that TRIM21 is released upon lytic cell death (pyroptosis or necroptosis) but not apoptosis. Although many cytosolic proteins are released by dead cells, liberated TRIM21 is distinct: Its high antibody affinity enables binding to Fc domains of circulating immunoglobulins, forming large immune complexes (ICs). These ICs increase in SjD, where anti-TRIM21 autoantibodies interact with released TRIM21 via Fc and F(ab′) 2 . TRIM21 ICs are taken up by macrophages, which drive proinflammatory responses, antigen presentation, and metabolic changes in high interferon environments. Thus, TRIM21 may perpetuate inflammation and autoantigen presentation, resulting in high immunogenicity.
- 17 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (118) , eads9680
The autoantigen TRIM21 assembles proinflammatory immune complexes after lytic cell death
Sjögren’s disease (SjD) causes localized and systemic inflammation and autoantibody production against intracellular proteins such as TRIM21/Ro52 (tripartite motif-containing protein 21). TRIM21, an E3 ubiquitin ligase, binds antibody Fc domains on opsonized pathogens that have escaped extracellular immunity and entered the cytosol. TRIM21 then ubiquitinates these pathogens, driving their proteasomal degradation. How TRIM21 becomes an autoantigen remains unclear. We show that TRIM21 is released upon lytic cell death (pyroptosis or necroptosis) but not apoptosis. Although many cytosolic proteins are released by dead cells, liberated TRIM21 is distinct: Its high antibody affinity enables binding to Fc domains of circulating immunoglobulins, forming large immune complexes (ICs). These ICs increase in SjD, where anti-TRIM21 autoantibodies interact with released TRIM21 via Fc and F(ab′) 2 . TRIM21 ICs are taken up by macrophages, which drive proinflammatory responses, antigen presentation, and metabolic changes in high interferon environments. Thus, TRIM21 may perpetuate inflammation and autoantigen presentation, resulting in high immunogenicity.